Bio Rad Ownership
| BIO Stock | USD 256.68 2.21 0.87% |
Shares in Circulation | First Issued 1985-09-30 | Previous Quarter 28 M | Current Value 28 M | Avarage Shares Outstanding 26 M | Quarterly Volatility 3.8 M |
Bio |
Bio Stock Ownership Analysis
About 16.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.09. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio Rad Laboratories has Price/Earnings To Growth (PEG) ratio of 1.19. The entity recorded a loss per share of 65.37. The firm had not issued any dividends in recent years. Bio Rad had 2:1 split on the 8th of March 2002. Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Bio-Rad Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 8200 people. For more info on Bio Rad Laboratories please contact Norman Schwartz at 510 724 7000 or go to https://www.bio-rad.com.Besides selling stocks to institutional investors, Bio Rad also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bio Rad's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bio Rad's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bio Rad Quarterly Liabilities And Stockholders Equity |
|
About 16.0% of Bio Rad Laboratories are currently held by insiders. Unlike Bio Rad's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bio Rad's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bio Rad's insider trades
Bio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Rad is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Rad Laboratories backward and forwards among themselves. Bio Rad's institutional investor refers to the entity that pools money to purchase Bio Rad's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 427.3 K | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 388.6 K | Millennium Management Llc | 2024-12-31 | 379.1 K | Geode Capital Management, Llc | 2024-12-31 | 322 K | Parnassus Investments Llc | 2024-12-31 | 310.9 K | Southeastern Asset Management Inc | 2024-12-31 | 308.5 K | Sei Investments Co | 2024-12-31 | 271.4 K | Bank Of New York Mellon Corp | 2024-12-31 | 267.3 K | Westfield Capital Management Company, L.p. | 2024-12-31 | 264.6 K | Blackrock Inc | 2024-12-31 | 2 M | Vanguard Group Inc | 2024-12-31 | 1.9 M |
Bio Rad Laboratories Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Rad insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Rad's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Rad insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allison Schwartz few days ago Disposition of tradable shares by Allison Schwartz of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Michael Crowley over a month ago Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Andrew Last over a month ago Disposition of 279 shares by Andrew Last of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Allison Schwartz over six months ago Disposition of tradable shares by Allison Schwartz of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Ilan Daskal over six months ago Acquisition by Ilan Daskal of 456 shares of Bio Rad subject to Rule 16b-3 | ||
Michael Crowley over six months ago Acquisition by Michael Crowley of 520 shares of Bio Rad subject to Rule 16b-3 | ||
Michael Crowley over six months ago Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Michael Crowley over six months ago Acquisition by Michael Crowley of 433 shares of Bio Rad subject to Rule 16b-3 |
Bio Rad's latest congressional trading
Congressional trading in companies like Bio Rad Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bio Rad by those in governmental positions are based on the same information available to the general public.
| 2022-04-08 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
Bio Rad Outstanding Bonds
Bio Rad issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Rad Laboratories uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Rad Laboratories has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIO 33 15 MAR 27 Corp BondUS090572AR99 | View | |
| BIO 37 15 MAR 32 Corp BondUS090572AQ17 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Bio Rad Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 4th of March 2025 Other Reports | ViewVerify | |
8K | 21st of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 14th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving together with Bio Stock
Moving against Bio Stock
| 0.84 | LUCD | Lucid Diagnostics | PairCorr |
| 0.83 | CPIX | Cumberland Pharmaceuticals | PairCorr |
| 0.82 | CMRX | Chimerix | PairCorr |
| 0.79 | LUNG | Pulmonx Corp | PairCorr |
| 0.75 | INMD | InMode | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (65.37) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.